RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia

Leukemia

Volumn 18, Issue 4, 2004, Pages 685-692

  Perentesis, J P ^a,g   Bhatia, S ^b   Boyle, E ^c   Shao, Y ^d   Shu, X Ou ^d   Steinbuch, M ^e   Sather, H N ^f,g   Gaynon, P ^h   Kiffmeyer, W ^d   Envall Fox, J ^d   Robison, L L ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Child Hosp Ctrl California/UCSF   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Health Care Research Center   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g CHILDREN S ONCOLOGY GROUP   (United States)

^h CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Chemotherapy; Child; Leukemia; Mutation; Oncogene; RAS

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; RAS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALGORITHM; ARTICLE; B CELL LEUKEMIA; BLAST CELL; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CODON; CONTROLLED STUDY; DNA DETERMINATION; EXON; FEMALE; GENDER; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RISK FACTOR; STATISTICAL SIGNIFICANCE; TESTIS DISEASE;

EID: 13544268759     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403272     Document Type: Article

References (43)

1. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071-1079.
2. Bos JL. All in the family? New insights and questions regarding interconnectivity of RAS, Rap1 and Ral. EMBO J 1998; 17: 6776-6782.
3. Barbacid M. RAS oncogenes: their role in neoplasia. Eur J Clin Invest 1990; 20: 225-235.
4. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-RAS exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 1990; 87: 3042-3046.
5. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR. Harvey murine sarcoma virus p21 RAS protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 1984; 3: 2581-2585.
6. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
7. Lubbert M, Mirro Jr J, Miller CW, Kahan J, Isaac G, Kitchingman G et al. N-RAS gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 1990; 75: 1163-1169.
8. Yokota S, Nakao M, Horiike S, Seriu T, Iwai T, Kaneko H et al. Mutational analysis of the N-RAS gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol 1998; 67: 379-387.
9. Robison LL, Buckley JD, Bunin G. Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group epidemiology program. Environ Health Perspect 1995; 103: 111-116.
10. Linet MS, Hatch EE, Kleinerman RA, Robison LL, Kaune WT, Friedman DR et al. Residential exposure to magnetic fields and acute lymphoblastic leukemia in children (see comments). N Engl J Med 1997; 337: 1-7.
11. Lubin JH, Linet MS, Boice Jr JD, Buckley J, Conrath SM, Hatch EE et al. Case-control study of childhood acute lymphoblastic leukemia and residential radon exposure. J Natl Cancer Inst 1998; 90: 294-300.
12. Brondum J, Shu XO, Steinbuch M, Severson RK, Potter JD, Robison LL. Parental cigarette smoking and the risk of acute leukemia in children. Cancer 1999; 85: 1380-1388.
13. Shu XO, Stewart P, Wen WQ, Han D, Potter JD, Buckley JD et al. Parental occupational exposure to hydrocarbons and risk of acute lymphocytic leukemia in offspring. Cancer Epidemiol Biomarkers Prev 1999; 8: 783-791.
14. Neglia JP, Linet MS, Shu XO, Severson RK, Potter JD, Mertens AC et al. Patterns of infection and day care utilization and risk of childhood acute lymphoblastic leukaemia. Br J Cancer 2000; 82: 234-240.
15. Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, Tannous R et al. Intensification of therapy for children with lower risk acute lymphoblastic leukemia: long-term follow-up of patients treated on CCG trial 1881. J Clin Oncol 2003; 21: 1790-1797.
16. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W et al. Double delayed intensification improves event-free survival for children with intermediate risk acute lymphoblastic leukemia. Blood 2002; 99: 825-833.
17. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high risk acute lymphoblastic leukemia. N Engl J Med 1998; 338: 1663-1671.
18. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1612-1617.
19. Boyle EB, Steinbuch M, Tekautz T, Gutman JR, Robison LL, Perentesis JP. Accuracy of DNA amplification from archival hematological slides for use in genetic biomarker studies. Cancer Epidemiol Biomarkers Prev 1998; 7: 1127-1131.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Tarone RE, Ware J. On distribution-free tests for equality of survival distribution. Biometrika 1977; 64: 156-160.
22. Cox DR. Regression models and life-tables. J Statist Soc B 1972; 34: 187-220.
23. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res 1999; 23: 115-126.
24. Nakao M, Janssen JW, Seriu T, Bartram CR. Rapid and reliable detection of N-RAS mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 2000; 14: 312-315.
25. Rodenhuis S, Bos JL, Slater RM, Behrendt H, van't Veer M, Smets LA. Absence of oncogene amplifications and occasional activation of N-RAS in lymphoblastic leukemia of childhood. Blood 1986; 67: 1698-1704.
26. Terada N, Miyoshi J, Kawa-Ha K, Sasai H, Orita S, Yumura-Yagi K et al. Alteration of N-RAS gene mutation after relapse in acute lymphoblastic leukemia. Blood 1990; 75: 453-457.
27. Senn HP, Tran-Thang C, Wodnar-Filipowicz A, Jiricny J, Fopp M, Gratwohl A et al. Mutation analysis of the N-RAS proto-oncogene in active and remission phase of human acute leukemias. Int J Cancer 1988; 41: 59-64.
28. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 1988; 85: 9268-9272.
29. Browett PJ, Norton JD. Analysis of RAS gene mutations and methylation state in human leukemias. Oncogene 1989; 4: 1029-1036.
30. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75: 1684-1690.
31. Mangues R, Pellicer A. RAS activation in experimental carcino-genesis. Semin Cancer Biol 1992; 3: 229-239.
32. Kelly MJ, Johnson BE. Molecular biology of lung cancer. In: Mendelsohn J, Howeley PM, Israel MA, Liotta LA (eds). Molecular Basis of Cancer, 2nd edn. Philadelphia PA: WB Saunders, 2001, pp 260-287.
33. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-RAS oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991; 83: 1024-1027.
34. Feng Z, Hu W, Chen JX, Pao A, Li H, Rom W et al. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst 2002; 94: 1527-1536.
35. Lemoine NR, Mayall ES, Williams ED, Thurston V, Wynford-Thomas D. Agent-specific RAS oncogene activation in rat thyroid tumours. Oncogene 1988; 3: 541-544.
36. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA et al. Activated RAS oncogenes in human thyroid cancers. Cancer Res 1988; 48: 4459-4463.
37. van't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9: 3114-3116.
38. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
39. LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB et al. RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 1989; 73: 889-891.
40. Perentesis JP, Siever EL. Targeted therapies for high risk acute myeloid leukemia. Hematol Oncol Clin N Am 2001; 15: 677-701, viii-ix.
41. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P et al. Loss of NF1 results in activation of the RAS signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996; 12: 144-148.
42. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267-272.
43. Sawyers CL, Denny CT. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 1994; 77: 171-173.